arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

DYADIC INTERNATIONAL INC

DYAI
$1.01 ▲ +0.02 (+1.51%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

DYADIC INTERNATIONAL INC faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 182.3%
Op. Margin -171.3%
ROIC 368.7%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.11M
↑ +182.3%
Net Income Profit after all expenses
$-1.95M
↑ +3.6%
Operating Margin Operating profit as % of sales
-171.3%
↑ +36.9% 0th
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
25
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters